248 results on '"Rametta, Raffaela"'
Search Results
2. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis
3. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells
4. GNPAT rs11558492 is not a Major Modifier of Iron Status: Study of Italian Hemochromatosis Patients and Blood Donors
5. MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease
6. The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids
7. Statin use and non-alcoholic steatohepatitis in at risk individuals
8. Dietary Iron Overload Induces Visceral Adipose Tissue Insulin Resistance
9. GNPAT p.D519G variant and iron metabolism during oral iron tolerance test
10. The rs2294918 E434K Variant Modulates Patatin-Like Phospholipase Domain-Containing 3 Expression and Liver Damage
11. Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD
12. PNPLA3 I148M Variant Influences Circulating Retinol in Adults with Nonalcoholic Fatty Liver Disease or Obesity1,2
13. The UCP2 -866 G>A promoter region polymorphism is associated with nonalcoholic steatohepatitis.
14. Paradoxical Dissociation Between Hepatic Fat Content and De Novo Lipogenesis Due to PNPLA3 Sequence Variant
15. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease
16. PCSK9 rs11591147 R46L loss‐of‐function variant protects against liver damage in individuals with NAFLD
17. Hepatic steatosis and PNPLA3 I148M variant are associated with serum Fetuin-A independently of insulin resistance
18. Hepatic notch signaling correlates with insulin resistance and nonalcoholic fatty liver disease
19. PCSK9 rs11591147 R46L loss‐of‐function variant protects against liver damage in individuals with NAFLD
20. Patatin-Like Phospholipase Domain-Containing 3 I148M Polymorphism, Steatosis, and Liver Damage in Chronic Hepatitis Cσ
21. TM6SF2/PNPLA3/MBOAT7 loss-of function genetic variants impact on NAFLD development and progression both in patients and in in vitro models
22. The PSRC1 rs599839 A > G variant disentangles the risk of coronary artery disease and hepatocellular carcinoma in Italian NAFLD patients
23. A polygenic risk score for progressive non-alcoholic fatty liver disease risk stratification
24. Validation of interleukin-32 as a new circulating fatty liver biomarker
25. From Environment to Genome and Back: A Lesson from HFE Mutations
26. Dysmetabolic Hyperferritinemia and Dysmetabolic Iron Overload Syndrome (DIOS): Two Related Conditions or Different Entities?
27. Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes
28. Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker
29. Impact of natural neuromedin‐B receptor variants on iron metabolism
30. Increased Expression and Activity of the Transcription Factor FOXO1 in Nonalcoholic Steatohepatitis
31. α1-Antitrypsin mutations in NAFLD: High prevalence and association with altered iron metabolism but not with liver damage
32. The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: TMPRSS6 and hepcidin in hemodialysis
33. The i148m Pnpla3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls
34. PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients
35. LBP-32-The Natural History of Ferroportin Disease-First Results of the International, Multicenter EASL non-HFE Registry
36. FRI-320-TM6SF2 silencing impairs lipid metabolism and trafficking in HepG2 cells carrying the I148M PNPLA3 variant and MBOAT7 deletion
37. PS-005-Evaluation of neuromedin-B receptor variants effect on iron metabolism and liver disease
38. PS-006-MBOAT7 downregulation induces hepatic lipid accumulation
39. SAT-275-Interleukin-32 as a novel NAFLD biomarker in PNPLA31148M variant carriers
40. MBOAT7 Down-Regulation by Hyperinsulinemia Induces Fat Accumulation in Hepatocytes
41. Genetic and Epigenetic Modifiers of Alcoholic Liver Disease
42. Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study
43. Impact of natural neuromedin‐B receptor variants on iron metabolism.
44. Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease
45. Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease
46. GNPAT p.D519G variant and iron metabolism during oral iron tolerance test
47. Proprotein convertase 7 rs236918 associated with liver fibrosis in Italian patients with HFE‐related hemochromatosis
48. The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent
49. Hepcidin resistance in dysmetabolic iron overload
50. The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development – a potential therapeutic target?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.